MNU - Faculty of Pharmacy Newsletter - Vol. 1 - Issue 1

Under

Prof. Cherif Khater

EDITOR-IN-CHIEF

Assoc. Prof. Ahmed R. ElSheakh

EDITOR

Dr. Bassant Maher

President Speech

Dear Pharmacy Community,

I am thrilled to announce the launch of the first volume of our pharmacy newsletter at Mansoura National University, to share with you the exciting news, achievement and student participations .

In this 1st issue of our Newsletter, we represent our commitment to sharing the important work being done by our staff and students with a wider audience. With each issue, we hope to showcase the incredible research, teaching, and patient care being done by our students, and staff.

In this first issue, you will find articles on a range of topics, including updates on groundbreaking topics, achievements of faculty members and students, and news on upcoming events and initiatives.

I encourage you to read through this issue and to share it with your colleagues and friends. By doing so, you are helping to spread awareness of the important work being done by our pharmacy staff and students to support our mission of excellence in education and research.

Thank you for your continued dedication to the field of pharmacy, and I look forward to the many exciting accomplishments we will achieve together in the future.

Sincerely,

Prof. Cherif Khater University President

Program Director Speech

Dear colleagues,

We are pleased to welcome you all to our faculty Newsletter. As we approach the end of our first academic year, we are proud to share with you the many accomplishments and successes of our students, faculty, and staff.

As Editor-in-Chief, I am honored to lead the publication of this Newsletter and provide a platform for our faculty community to share their stories and achievements. This year, we have received a record number of submissions, which is a testament to the incredible work and dedication of our students and faculty.

As Program Director, I want to express my gratitude to our outstanding faculty members who have gone above and beyond to support our students during these challenging times. Their commitment to teaching and service has made a positive impact on the lives of our students and the wider community.

In this Newsletter, you will find articles and updates on our academic programs, community outreach, and student activities. We hope that you will find these stories inspiring and informative, and that they will showcase the many achievements of our faculty community.

Once again, thank you for your contributions to this Newsletter, and we look forward to another successful year ahead.

Sincerely,

Ahmed R ElSheakh

Chapter I

Global Trends 2023

The History Repeats Itself !

«Will artificial intelligence be the mirror of the industrial revolution attack?»

Artificial intelligence (AI) has gained recent public prominence with the release of deeplearning models that can generate anything from art to term papers with minimal human intervention. The growth of this science and its applications in all areas of life is accelerating in an unprecedented way, so that it now touches every aspect of our lives, and its cognitive and absorptive capabilities are qualified to exceed human capabilities. On the other hand, they increase the possibility of risks that may force us to have undesirable effects. If AI can bring good consequences, then it can likewise have dire ones for human societies, environment, ecosystems, human life, and even the human mind, given the new ways which affect how people think, interact, and make decisions.

As regards to using AI applications in medical and pharmacy fields, it appears as one in which there is tremendous potential along with equally substantial challenges. For example, it has been used for diagnostic support, predictive analytics, personalized

The Question here,

medicine, imaging analysis, drug discovery, telemedicine, and surgical support.

More recently, AI has been used in the writing process of research papers. Subsequently, a number of journals added specific instructions that needed to be followed in their guide for authors› sections for those who use generative AI and AI-assisted technologies in their writing process. Additionally, using these technologies in a research paper has been added to be checked in the plagiarism checker engines.

Will all people cope blindingly with these technologies in all their daily life?

The other face of many scientists and public figures opinions

A group of scientists drafted an open letter that was successively approved and signed by many scientists and public figures, including Elon Musk, who is one of Open AI’s cofounders, proposing to stop developing software experiments more powerful than GPT-4 (the latest version of the large language model software developed by U.S. startup Open AI) for six months to review what has

been produced so far and make sure it does not harm humanity before going beyond that.

And if this step is not done, they will call on governments to intervene quickly to impose this stop. They also call on laboratories and experts to take advantage of this downtime to develop a set of safety agreements that regulate the development of AI systems so that they are supervised and monitored by other

independent experts. However, this does not mean a complete cessation of the development of all forms of AI in general, but only the cessation of the frantic race to produce systems whose potential is unpredictable [1] .

Also, some Arab scholars and professors have designed their own an open letter to be signed also [2] .

Finally, what is your opinion?

Will you support using AI in all our fields without restrictions?

Or, you will disagree it totally as some workers feared in the past?

Or, you will go to sign this commitment?

Captured on 12th April, 2023

The Director-General of UNESCO responded to this letter by appealing to the world’s governments to abide by the November 2021 Ethical Recommendation for Artificial Intelligence, which has been approved by every country in the world [3,4]. Also, TIME magazine published an article saying that six months is not enough and suggesting a complete halt to these advanced experiments [5] .

Concerning some people’s fear of losing their traditional jobs with these inserted technologies, these responses are natural and expected, as the human outstanding doubt of any new aspects that might replace humanity. And what happened in 18-19th centuries, particularly during the first industrial revolution can teach us about the possible coming upset in the job market with AI use, as workers at this time had the experience of being suddenly thrown out of their jobs by automation. But rather than accept it, they fought back, attacked, and destroyed machines.

But it is expected that people will adapt to these changes and technologies that looked strange at the beginning, particularly when they could find the pros of these issues in saving time and effort with some accurate outcomes. Additionally, new job opportunities will be created for those who were able to take advantage of AI technologies.

For more details check the following:

1. https://futureoflife.org/open-letter/pause-giant-aiexperiments

2. https://docs.google.com/document/d/1_qKOmhcve9GPry9yFsmoS-9joSyeqO9Lkd429gCLtA/ edit?usp=sharing

3. https://www.unesco.org/en/articles/artificialintelligence-unesco-calls-all-governments-implementglobal-ethical-framework-without

4. https://unesdoc.unesco.org/ark:/48223/ pf0000380455_ara

5. https://time.com/6266923/ai-eliezer-yudkowskyopen-letter-not-enough/

Top 10 Pharma Industry Trends & Innovations in 2023

Keep tracking and cope with the job opportunities and facilities in pharmacy field that you may ignore.

Data from StartUs are summarized and illustrated as the following:

1. Artificial Intelligence

Pangaea Data – Patient Cohort Identification: is a British startup that uses unsupervised AI algorithms to identify patient cohorts for drug discovery, clinical trials, and real-world evidence (RWE) studies.

InVivo AI – Drug Discovery: for drug discovery.

2. Big Data & Analytics

Pryml – Secure Data Collaboration: creates a synthetic version of the confidential data available with pharmaceutical companies.

Pomicell – In-Silico Modeling: for big data analytics in pharmaceutical research and development (R&D).

3. Flexible Production

Cellexus – Single-Use Bioreactor: makes single-use airlift bioreactor systems. The startup’s patented airlift technology uses bubbles instead of mechanical mixing to move cells and nutrients.

Secoya Technologies – Continuous Manufacturing Optimisation: tailoring the continuous manufacturing process equipment down to the ideal scale.

4. Precision Medicine

ExactCure – Drug Exposure Model: for simulating the effects of drugs in a patient’s body based on personal characteristics.

Tepthera – Individualized Cancer Vaccine: offers platform technologies for the identification of T cell antigens.

5. Additive Manufacturing

FabRx – Printed Pill: a 3D printer for making personalized pills that uses proprietary technology for direct powder extrusion.

Frontier Bio – Tissue Bioprinter: a 3D bioprinter for making human tissues.

6. Blockchain

PharmaTrace – Smart Contracts: offers a blockchain-based ecosystem to secure data and deploy smart contracts in the pharmaceutical industry.

Veratrak – Pharma Supply Chain: offers a blockchain-based document collaboration and workflow management platform for the pharmaceutical supply chain.

7. Extended Reality (XR)

Nanome – VR Collaboration Tool: offers virtual reality collaboration tools for atomic, molecular, and protein visualization.

Goodly Innovations – AR Suite: an augmented reality suite for pharma and biopharma manufacturing.

8. Real-World Data

Graticule – Unstructured Patient Data: makes use of clinical notes, free text, and images, as well as non-clinical data for data completeness.

OncoChain – Oncological Data: offers a research platform based on a de-identified real-world oncological patient database.

9. Digital Therapeutics

Cognivive – Neuro-Rehabilitation: offers evidence-based digital therapeutics for the treatment of neurocognitive and neuromotor impairments.

Dopavision – Eye Treatment: a smartphonebased digital therapeutic for myopia.

10. Curative Therapies

Mogrify – Cell Therapy: a proprietary direct cellular conversion platform to transmogrify any mature human cells.

Lacerta Therapeutics – Gene Therapy: a clinical-stage gene therapy startup working on cures for the central nervous system and lysosomal storage diseases.

Top 10 Innovation trends on pharma industry

Top

innovation trends and thier impact on the pharma industry

Reference:

https://www.startus-insights.com/innovators-guide/top10-pharma-industry-trends-innovations-in-2021/

Chapter II

On Fire From the top FDA’s actions in 2023

FDA’s decision to withdraw approval

of Makena

The US Food and Drug Administration (FDA) announced on April 6, 2023, that it has decided to withdraw approval of Makena and its generic versions.

Makena is a progestin that was approved in 2011 to reduce the risk of preterm birth in women with a previous spontaneous preterm birth. The treatment had been approved under an accelerated pathway based on a determination that the sponsor had demonstrated a drug effect on an intermediate clinical endpoint that was reasonably likely to predict clinical benefit. The agency’s approval included a requirement that the sponsor conduct a post-marketing confirmatory study.

In the years since Makena was approved, the drug’s sponsor Covis says, about 350,000 women have been treated with it. But a large 2019 study failed to show that it actually prevented preterm birth. Subsequently, the agency proposed withdrawing the drug in 2020, but Covis requested a hearing on the decision, and that meeting was held in October 2022.

The FDA commissioner and chief scientist subsequently reviewed the submitted reports, comments, and transcripts, and made the decision to withdraw the drug. “Effective today, Makena and its generics are no longer approved and cannot lawfully be distributed in interstate commerce,” the agency said. “It is tragic that the scientific research and medical communities have not yet found a treatment shown to be effective in preventing preterm birth and improving neonatal outcomes — particularly in light of the fact

that this serious condition has a disparate impact on communities of color, especially Black women,” FDA Commissioner Robert M. Califf, MD, said in a statement about the decision.

Risks associated with the drug include thromboembolic disorders, allergic reactions, decreased glucose tolerance, and fluid retention, regulators have noted. The agency acknowledged that some supplies of the product have already been distributed. Patients with questions should talk to their healthcare provider, the FDA advised.

Reference:

https://www.fda.gov/news-events/pressannouncements/fda-commissioner-andchief-scientist-announce-decision-withdrawapproval-makena

FDA approves first over-thecounter Narcan

On 29th March 2023, the FDA approved Narcan, an opioid overdose reversal drug, to be sold without a prescription. Narcan can now be sold in gas stations, convenience

stores and grocery stores. The approval marks the first time any form of naloxone will be available without a prescription that will increase the number of locations where it’s available and help reduce opioid overdose deaths. The drug, which first received FDA approval in 1971, was originally an injection. The FDA approved the inhaled nasal spray version, more commonly known as Narcan, in 2015. It contains 4 mg of naloxone that can be sprayed into the nose like a common allergy medication.

Reference:

https://www.fda.gov/news-events/pressannouncements/fda-approves-first-overcounter-naloxone-nasal-spray

First oral treatment for Anemia caused by Chronic Kidney Disease

FDA authorizes first at-home combo flu/Covid test

The FDA on 24th February 2023, authorized emergency use of the first over-the-counter test that can detect both Covid-19 and flu. The single-use test, made by Lucira Health, is able to differentiate between influenza A and B as well as Covid. It takes about 30 minutes to get results from a self-collected nasal swab.

Reference:

https://www.fda.gov/news-events/pressannouncements/fda-authorizes-first-overcounter-home-test-detect-both-influenzaand-covid-19-viruses

The FDA on 1st February 2023 approved Jesduvroq tablets (daprodustat) as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been receiving dialysis for at least four months. Jesduvroq is not approved for patients who are not on dialysis.

Reference:

https://www.fda.gov/news-events/pressannouncements/fda-approves-first-oraltreatment-anemia-caused-chronic-kidneydisease-adults-dialysis

Chapter II

Novel Drug Approvals for 2023

Innovative drugs often mean new treatment options for patients and advances in health care. Each year, FDA’s Center for Drug Evaluation and Research (CDER) approves a wide range of new drugs and biological products. Some of these products have never been used in clinical practice. Below is a listing of new molecular entities and new therapeutic biological products that CDER approved in 2023.

To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise

To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor

To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

To treat anemia caused by chronic kidney disease for adults on dialysis for at least four monthsPress Release

To treat non-central nervous system manifestations of alpha-mannosidosis

To reduce proteinuria in adults with primary immunoglobulin

A nephropathy at risk of rapid disease progression

To treat metastatic or recurrent locally advanced Merkel cell carcinoma

Reference:

https://www.fda.gov/drugs/new-drugs-fda-cdersnew-molecular-entities-and-new-therapeuticbiological-products/novel-drug-approvals-2023

FDA Expands Atogepant Approval to Include Chronic Migraine

The FDA has approved an expanded indication for atogepant (Qulipta, Abbvie) to include prevention of chronic migraine in adults. The approval makes atogepant the first, and only, oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic.

The FDA initially approved atogepant in 2021 for prevention of episodic migraine in adults. Once-daily atogepant is available in three doses — 10 mg, 30 mg, and 60 mg — for prevention of episodic migraine. However, only the 60 mg dose of medication is indicated for the preventive treatment of chronic migraine.

This expanded indication is based on positive results of the phase 3 PROGRESS trial that met the primary endpoint of statistically

significant reduction from baseline in mean monthly migraine days with atogepant compared with placebo across the 12week treatment period. Treatment with atogepant also led to statistically significant improvements in all six secondary endpoints, including the proportion of patients that achieved at least a 50% reduction in mean monthly migraine days across 12 weeks and improvements in function and reduction in activity impairment due to migraine.

The overall safety profile of atogepant is consistent with the episodic migraine patient population, with the most common adverse events including constipation, nausea, and fatigue/sleepiness. The FDA approval is an important milestone, providing those most impacted by migraine with a new, safe, and effective treatment option in a convenient, once-daily pill.

Reference:

https://www.medscape.com/viewarticle/991371

Chapter III

Activities & Achievements

Student Scientific Team’s Success Journey

The first attended conference with its achievements & winning ranks

The student scientific team at the Faculty of Pharmacy, Mansoura National University (MNU) was established in February 2023 under the supervision of Assoc. Prof. Ahmed Ramadan ElSheakh - acting dean of the college - and Dr. Bassant Maher - coordinator of student scientific training - to be the first activity in the university that directs students to deal with practical scientific life in a realistic way and give them the opportunity to participate in events and research developments inside and outside the university, which is Keeping pace with Egypt’s vision 2030, especially in its axis of innovation, knowledge, and scientific research.

From the activities and responsibilities of the students in this team:

1.Organizing scientific conferences, events, and seminars.

2.Participation in scientific conferences through presentations or posters of scientific research, or other active participation.

3.Participation in the college’s research plans.

4.Conducting their own scientific research with the capability of publishing them.

5.Aware and educate colleagues and community with medical and pharmaceutical topics through videos, brochures, and other publishing materials.

6.Participation in medical convoys and other community services.

The first task of the team was to participate with scientific topics and research articles in the 4th student conference that was held at the Delta University for Science and Technology on March 12th, 2023 that covered student participation from different colleges around the Egyptian Republic. This task was important, interesting, but challenging as the limited time and experience of the students in their first year at the pharmacy colleges. While and according to the established plan, periodic meetings, well-done preparation, and ambitious brilliant students, the task was performed in a professional way and the students won two places from all ones at the conference.

MNU Pharmacy scientific students who won places at the conference

2nd place for the best oral presentation

Aseel Mohammed

Israa nasser

Sara Mohammed

Omnia mohammed

Raghad kandil

Reham ahmed

Outstanding participation with oral presentation place

Shahd Ahmed

Ghada Gamal

Yasmeen Ahmed

Hana Tarek

Hanin Ibrahim

Shrook Mohamed

Pharmacovigilance Awareness Day

On Tuesday, March 14th 2023, the Faculty of Pharmacy MNU organized a scientific day entitled “Pharmacovigilance Awareness Day”.

The activities of this day started with a presentation introduced by Dr. Bassant Maher about the concept of pharmacovigilance (PV), its importance, why we need PV, and the responsibility of the healthcare providers for detecting and reporting the adverse effects resulting from the use of medicines and pharmaceutical products or any other medical related problem. Also, she trained students about ways for these reporting tasks to the Egyptian Pharmaceutical Vigilance Center (EPVC) of the Egyptian Drug Authority (EDA).

The other part of the day included awareness activities performed by the attended university students who educated other university staff and students about this concept and reporting mechanisms.

The First Students Scientific Day

The Faculty of Pharmacy held on Tuesday, March 7th 2023, the activities of “the first student scientific day”, under the Patronage of Prof. Cherif Khater (University President), under supervision of Assoc. Prof. Ahmed Ramadan ElSheakh - program director - and Dr. Bassant Maher, with the presence of Programs Directors : Prof. Dr. Amira Taman, Prof. Dr. Noha AlWasifi - and Asst. Prof. Ihab Abdel Hay and Prof. Dr. Rania Al-Shahini - Professor at the College of Pharmacy.

During the day, 11 MNU pharmacy scientific students introduced various scientific topics that have been discussed and evaluated by a specialized committee of MNU professors.

The day objectives were to disseminate the scientific information searched by the students, strengthen their presentation, communication, and research skills, added to discover students’ talents, abilities, and creativity in the research field.

Those students were:

- Hossny Mohamed Abdelhafez

- Yasmeen Ahmed Elagamy Sakrana

- Hana Tarek Elsaed khodir

- Shrook Mohamed Elsaid Abdullah

- Nada Mohammed Ismail Mohammed

- Aseel Mohammed Elsayed Hassan

- Sara Mohammed mansour abdelgawad

- Raghad kandil fathy Elsayed

- Amira Mosaad Aboelftouh

- Malak Hisham Ibrahim

- Farah Hamdy Meki

Student Activities in the Pharmacognosy Term II, 2022/2023

Under the supervision of Dr. Yehia Amin, assistant professor of pharmacognosy MNU Faculty of Pharmacy, who asked to design herbal products that work as laxatives or topical ones for rheumatism and circulatory problems. The students searched the data and gathered different herbal products together in one product with guessing the suitable price for this and, they also clarified the uses of each ingredient ,depending on their educational knowledge, to form the uses of each ingredient to form a final product with the needed indications.

The faculty students demonstrated wonderful fulfillment and their activities were collected in one book as illustrated.

Signed Protocols and Partnerships

In

the first year of the MNU Faculty of Pharmacy

The Faculty of Pharmacy at Mansoura National University signed a cooperation protocol with the Egyptian Drug Authority (EDA) on 1st February 2023. The protocol aimed at developing the skills of students and graduates and providing them with the necessary skills and competencies to keep pace with the requirements of the local and global labor market and contribute to the development of the professional path.

Assoc. Prof. Ahmed Ramadan ElSheakh - Director of the PharmD Program - Clinical Pharmacy at the MNU Faculty of Pharmacy signed the protocol on the part of Mansoura National University, and Prof. Dr. Ayman Al-Khatib - EDA Vice President on the EDA side, in the presence of Dr. Rasha Ziadeh - Assistant to the President of the Commission for Technical Development and Capacity Development, and Dr. Walid Amir - Faculty of Pharmacy at Mansoura National University. Signing of the protocol comes within the framework of the faculty’s vision on raising the professional, scientific, and research level of their students, preparing trained cadres at the highest level, qualifying them for the labor market, and providing them with the expertise and skills necessary to keep pace with global developments in the field of pharmaceuticals.

https://www.mansnu.edu.eg/news-ar/2023-02-01-16-32-38

Chapter IV

Chapter IV

The top ten ranked students for the first semester 2022/2023

Pharmacy students who won the Ramadan Religious Competition at the university level that was held in Ramadan 2023

Nada Sameh Ali Co-president Rawan moheb El-shafey President

Hossny Mohamed Abdelhafez Member

Hager Gamal Mohamed Member Mennatollah Mohamed Member

Hanaa Mohamed El-morsy Member

Editorial Board

Editor in Chief

Assoc.Prof. Ahmed R ElSheakh

Editor

Assoc.Prof. Yhiya Amen

Dr. Bassant Maher

Dr. Randa Hani

Dr. Eman Yosrey

Graphic Design

Hamada Hamdy

Thanks To Our Students:

Assistant Content Editors

Ahmed Abdallah Elsebaey

Mariam Maher Mohamed

Mohamed shaher Mohamed

Ahmed Sameh Mohamed

Video Editors

Rehab Ehab Elmamlouk

Nada sameh ali tag

Samia Raed Mohammed Samy

Nour Mohamed mounir

Radwa wael awad gouda

Special Thanks

Special Thanks for Faculty Staff :

- Prof. Rania El Shahiny

- Dr. Ghada EL Emam

- Dr. Yhiya Amen

- Dr. Yousra EL Far

- Dr. Samar Samir

- Dr. Noha Osama Mansour

- Dr. Bassant Maher

- Dr. Walid Amir

- Dr. Hamed EL Shafey

- Dr. Abdullah Haikal

- Dr. Randa Hany

- Dr. Eman yosry

- Dr. Amgad Salem

- Dr. Yomna EL Lethi

- Dr. Badeaa Zakaria

- Dr. Diaa Fakhry

- Dr. Shreen Nabwi

- Dr. Kareem El Meadawie

- Mr. Amir Philip

VISION

Leadership and innovation in pharmaceutical education, training, scientific research, and community service within the framework of sustainable development to reach a prominent position regionally and internationally in the field of pharmacy.

MISION

Our goal is to prepare qualified pharmacists regionally and internationally, following the latest scientific and professional standards that are commensurate with the needs of the labor market and the scientific community. We aim to instill the values and ethics of the pharmacy profession while enabling our graduates to compete and keep pace with scientific and technological developments to raise the efficiency of the treatment system and achieve sustainable growth.

STRATEGIC GOALS

1- Supporting and developing the education, learning, and student support system.

2- Developing the capabilities of the college’s human resources from faculty members, assistant staff, technicians, and administrative staff.

3- Preparing distinguished graduates who can compete, link them to the college, and meet the needs of the labor market while supporting the goals of sustainable development.

4- Maximizing community participation and building local and international partnerships.

5- Establishing an applied scientific research system and constantly strengthening it.

6-Sustaining the infrastructure and developing the college’s resources.